▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #899 by analyst upside · 2026-09-27
CLDX
Celldex Therapeutics, Inc.
Healthcare · Market Cap $2B · P/E 0x
ANALYST PRICE TARGET
+101.0%
implied upside to consensus target
Current Price $31.1
Consensus Target $62.5
Bull Target $100.0
Bear Target $28.0
Analysts Covering 14
ANALYST CONSENSUS - BUY
Strong Buy
2
Buy
11
Hold
1
Sell
0
52-Week Low $22.1
52-Week High $45.14
YTD Return +15.1%
FUNDAMENTALS
Market Cap $2B
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-4.35
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $0M
Profit Margin N/A
52-WEEK RANGE
52-Week Low $22.1
52-Week High $45.14
Current Price $31.1
Bear Target $28.0
Bull Target $100.0
● Now $31.1 ● Target $62.5
TRADING DATA
Avg Volume 1.2M
YTD Return +15.1%
Analyst Count 14
Consensus Buy
Upside to Target +101.0%
Last Updated 2026-09-27

ANALYST SUMMARY

Celldex Therapeutics, Inc. (CLDX) is currently trading at $31.1 with a Wall Street consensus price target of $62.5, implying potential upside of 101.0% over the next 12 months. 14 analysts currently cover CLDX, with a consensus rating of Buy - 93% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $100.0, while the most cautious has a target of $28.0.

CLDX operates in the Healthcare sector with a market capitalisation of $2B. The stock is up 15.1% year-to-date and is currently trading near the lower end of its 52-week range of $22.1 – $45.14.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

ADMA +81.2%
ADMA Biologics, Inc.
$2B · P/E 13.4x · Buy
PBH +45.5%
Prestige Consumer Healthcare Inc.
$2B · P/E 13.1x · Buy
GTBIF +106.5%
Green Thumb Industries Inc.
$2B · P/E 14.4x · Buy
ACAD +55.5%
Acadia Pharmaceuticals Inc.
$4B · P/E 9.3x · Buy
INVA +68.8%
Innoviva, Inc.
$1B · P/E 4.8x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for CLDX, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Leerink Partners - Reiterated
Outperform → Outperform 2026-09-23 29% win rate (7 calls)
Morgan Stanley - Reiterated
Overweight → Overweight 2026-09-23 Building track record
HC Wainwright & Co. - Reiterated
Buy → Buy 2026-09-22 31% win rate (48 calls)
Cantor Fitzgerald - Reiterated
Overweight → Overweight 2026-09-22 40% win rate (10 calls)
Morgan Stanley - Reiterated
Overweight → Overweight 2026-09-10 Building track record
Morgan Stanley - Reiterated
Overweight → Overweight 2026-08-07 Building track record
Barclays - Reiterated
Overweight → Overweight 2026-08-07 Building track record
Wells Fargo - Reiterated
Overweight → Overweight 2026-07-29 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
43
out of 100
Coverage depth
21/30
Consensus clarity
0/30
Vote unanimity
20/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →